• Je něco špatně v tomto záznamu ?

Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma

H. Gao, Y. Li, T. Lin, Y. Cheng, Y. Ma

. 2020 ; 164 (2) : 196-202. [pub] 20190821

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21014144

BACKGROUND: CIP2A has been proved to play a role as an oncogene in various types of malignancies while its functionality in renal clear cell carcinoma has not been investigated. Our study aimed to investigate the role of CIP2A in renal clear cell carcinoma and to explore the possible mechanisms. METHODS: A total of 80 patients with renal clear cell carcinoma and 32 healthy people were included in the study. Expression of CIP2A was detected by qRT-PCR. CIP2A silencing renal clear cell carcinoma cell line was established. Its effects on cell proliferation and migration were verified by CCK-8 assay and Transwell cell assay, respectively. The effects of CIP2A overexpression on AKT and VEGF were investigated. RESULTS: CIP2A expression level was increased in tumor tissues compared to adjacent healthy tissues. Serum levels of CIP2A protein were higher in cancer patients than in healthy controls, and serum levels of CIP2A protein were increased with increased stage of primary tumor. Serum CIP2A protein can be used to accurately predict renal clear cell carcinoma and its prognosis. CIP2A siRNA silencing inhibited tumor cell proliferation, and treatment with Akt activator reduced this inhibitory effect. CIP2A siRNA silencing decreased the expression level of VEGF and phosphorylation levels of AKT in renal clear cell carcinoma cells, while AKT activator treatment showed no significant effects on CIP2A expression. CONCLUSION: Downregulation of CIP2A can inhibit cancer cell proliferation and vascularization in renal clear cell carcinoma through inactivation of the Akt pathway and its downstream VEGF.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21014144
003      
CZ-PrNML
005      
20220420093332.0
007      
ta
008      
210504s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2019.031 $2 doi
035    __
$a (PubMed)31431792
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Gao, Hui $u Department of Urology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, P. R. China, 252000
245    10
$a Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma / $c H. Gao, Y. Li, T. Lin, Y. Cheng, Y. Ma
504    __
$a Literatura
520    9_
$a BACKGROUND: CIP2A has been proved to play a role as an oncogene in various types of malignancies while its functionality in renal clear cell carcinoma has not been investigated. Our study aimed to investigate the role of CIP2A in renal clear cell carcinoma and to explore the possible mechanisms. METHODS: A total of 80 patients with renal clear cell carcinoma and 32 healthy people were included in the study. Expression of CIP2A was detected by qRT-PCR. CIP2A silencing renal clear cell carcinoma cell line was established. Its effects on cell proliferation and migration were verified by CCK-8 assay and Transwell cell assay, respectively. The effects of CIP2A overexpression on AKT and VEGF were investigated. RESULTS: CIP2A expression level was increased in tumor tissues compared to adjacent healthy tissues. Serum levels of CIP2A protein were higher in cancer patients than in healthy controls, and serum levels of CIP2A protein were increased with increased stage of primary tumor. Serum CIP2A protein can be used to accurately predict renal clear cell carcinoma and its prognosis. CIP2A siRNA silencing inhibited tumor cell proliferation, and treatment with Akt activator reduced this inhibitory effect. CIP2A siRNA silencing decreased the expression level of VEGF and phosphorylation levels of AKT in renal clear cell carcinoma cells, while AKT activator treatment showed no significant effects on CIP2A expression. CONCLUSION: Downregulation of CIP2A can inhibit cancer cell proliferation and vascularization in renal clear cell carcinoma through inactivation of the Akt pathway and its downstream VEGF.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a autoantigeny $x genetika $7 D001324
650    _2
$a karcinom z renálních buněk $x krevní zásobení $x genetika $x patologie $7 D002292
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $x genetika $7 D002465
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genový knockdown $7 D055785
650    _2
$a lidé $7 D006801
650    _2
$a intracelulární signální peptidy a proteiny $x genetika $7 D047908
650    _2
$a nádory ledvin $x krevní zásobení $x genetika $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové proteiny $x genetika $7 D008565
650    _2
$a lidé středního věku $7 D008875
650    _2
$a patologická angiogeneze $x genetika $7 D009389
650    _2
$a protoonkogenní proteiny c-akt $x metabolismus $7 D051057
650    _2
$a vaskulární endoteliální růstový faktor A $x metabolismus $7 D042461
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Li, Yuqiao $u Department of Urology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, P. R. China, 252000
700    1_
$a Lin, Tao $u Department of Urology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, P. R. China, 252000
700    1_
$a Cheng, Yan $u Department of Urology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, P. R. China, 252000
700    1_
$a Ma, Yunbo $u Department of Urology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, P. R. China, 252000
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 164, č. 2 (2020), s. 196-202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31431792 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20210504 $b ABA008
991    __
$a 20220420093328 $b ABA008
999    __
$a ok $b bmc $g 1657557 $s 1134532
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 164 $c 2 $d 196-202 $e 20190821 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20210504

Najít záznam

Citační ukazatele

Možnosti archivace